Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).
Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning
Dr. Jane Smith, MD, Neurocritical Care Physician, MD
Assistant Professor of Neurology
•
University Hospital of Critical Care Medicine
“While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”
Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD
Senior Research Fellow
•
Institute for Brain Health Research
“In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”
Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH
Public Health Policy Advisor
•
National Stroke & Infection Control Coalition
“Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”